Litcius/Paper detail

Ibrexafungerp Demonstrates <i>In Vitro</i> Activity against Fluconazole-Resistant Candida auris and <i>In Vivo</i> Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis

Nathan P. Wiederhold, Laura K. Najvar, Marcos Olivo, Kelsey N. Morris, Hoja Patterson, Gabriel Catano, Thomas F. Patterson

2021Antimicrobial Agents and Chemotherapy53 citationsDOIOpen Access PDF

Abstract

Candida auris is an emerging pathogen that has rapidly spread to many countries on multiple continents. Invasive infections caused by this species are associated with significant mortality, and treatment options are limited due to antifungal resistance.

Topics & Concepts

Candida aurisFluconazoleFungal pathogenInvasive candidiasisIn vivoMicrobiologyPathogenBiologyAntifungalMycosisCandida infectionsIn vitroImmunologyBiochemistryBiotechnologyAntifungal resistance and susceptibilityFungal Infections and StudiesFungal Biology and Applications
Ibrexafungerp Demonstrates <i>In Vitro</i> Activity against Fluconazole-Resistant Candida auris and <i>In Vivo</i> Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis | Litcius